ABSTRACT The human factor VIII procoagulant protein (VIUC) was purified from the VIUC-factor VIII-related antigen (VIURAg) complex in commercial factor VIII concentrate by immunoadsorbent chromatography with a monoclonal anti-VIURAg antibody bound to Sepharose. In this complex, VHIC is noncovalently bound to factor VIJII-related antigen. The VIHC eluted from the complex was free of VIURAg as determined by immunoassay and had a specific activity of 2,294 VIUC units/mg of protein, representing a 164,000-fold purification from plasma. Electrophoresis of this VIUC preparation in reduced sodium dodecyl sulfate containing 5% polyacrylamide slab gels and subsequent staining with Coomassie blue showed the VUIC to be a strongly staining doublet ofMrs 79
The human factor VIII procoagulant protein (VIIIC) is a plasma protein that participates in the intrinsic pathway of blood coagulation. It is absent or defective in individuals with the hereditary X chromosome-linked recessive bleeding disorder, hemophilia A. The VIIIC protein circulates in blood as a complex with factor VIII-related antigen (VIIIRAg), a protein distinct from VIIIC in its biochemical properties, its role in primary hemostasis, and its inheritance pattern. The VIIIRAg protein is reduced or altered in individuals with the autosomal dominant bleeding disorder, von Willebrand disease (1) .
The biochemical and immunological characterization of VIIIC is important to the understanding of hemostasis and thrombosis, but its purification and study have been hindered by the difficulties inherent in purifying a plasma protein present in only trace amounts. Although the isolation and characterization of bovine VIIIC has been achieved with a 300,000-fold purification from plasma (2) , the highest degree of purification reported for human VIIIC has been 17,000-fold from plasma (3) .
We describe here a monoclonal antibody immunoadsorbent method for the purification of human VIIIC, which starts with commercial factor VIII concentrate and results in a 164,000-fold purification from plasma. The method yields enough VIIIC to produce and characterize a precipitating heterologous anti-human VIIIC antibody. Previous studies have been confined to the use ofnonprecipitating human anti-human VITIC antibodies of restricted immunoglobulin heterogeneity (4) . We have used this heterologous antibody in conjunction with the ample quantities ofVIIIC made available by the immunoadsorbent method to demonstrate Mr heterogeneity of VIIIC and changes in its Mr after thrombin treatment.
MATERIALS AND METHODS
Production of Monoclonal Anti-VIURAg Antibody. BALB/ c mice were immunized by intraperitoneal injection of 10 ,g of purified VIIIRAg (5) in complete Freund's adjuvant, and boosters in incomplete Freund's adjuvant were given twice at 2-wk intervals. A final booster was given without adjuvant 4 days before fusion. At 6 wk the mouse spleen cells were fused with P653 non-Ig-secreting mouse plasmacytoma cells (6) . Cell culture, solid-phase radioimmunoassay for anti-VIIIRAg antibodies, and production of monoclonal antibody in mouse ascites fluid were essentially as described by Liu et aL (7) .
Preparation and Regeneration of Immunoadsorbent. A monoclonal anti-VIIIRAg IgG was precipitated three times from ascites fluid by using 50% ammonium sulfate. After dialysis and centrifugation, the IgG was multiply adsorbed with 2.5% by volume ofa 2% aluminum hydroxide suspension (Armour Pharmaceutical, Tuckahoe, NY) and was treated twice with 2 mM diisopropyl fluorophosphate. This IgG preparation was coupled to 1.5 liters of CL-Sepharose 2B (Pharmacia) by the cyanogen bromide method (8) at an IgG density of 2-3 mg/ml of Sepharose.
Assays. Protein concentration was estimated by absorbance at 280 nm with bovine serum albumin as standard. All factor VIII assays were standardized by assigning the value of 1 unit/ ml to a frozen pool of20 normal plasmas. VIIIRAg was detected by Laurell immunoelectrophoresis (5) . This method detects the VIIIRAg in a 1:100 dilution of normal pooled plasma. Fibronectin was measured by Laurell immunoelectrophoresis, and fibrinogen was detected with antibody-coated latex beads (Burroughs Wellcome, Research Triangle Park, NC). Antibody inactivation ofVIIIC activity was measured in Bethesda units (9 (13) .
Production of Heterologous Antibody. An Australian emu (provided by the San Diego Zoo, San Diego, CA) was immunized with 100 units of purified VIIIC in complete Freund's adjuvant, and boosters were given weekly for 11 wkwith 60-400 units of purified VIIIC in incomplete Freund's adjuvant. Subsequent weekly boosters were without adjuvant. In 6 wk the anti-VIIIC antibody titer reached 600-900 Bethesda units/ml, and 50 ml of blood were taken weekly. Anti-serum was made monospecific by absorption with the factor VIII-depleted commercial concentrate that passed through the immunoadsorbent column during sample application (see preceding section).
Affinity Purification and Radiolabeling of Antibody. An affinity column was prepared by coupling purified VIIIC from 20 bottles of commerical factor VIII concentrate to 1 ml of cyanogen bromide-activated Sepharose 4B (Pharmacia). Twentyfive ml of absorbed antiserum was passed over the column. The column was washed with borate buffer (15) , and specific anti-VIIIC antibody was eluted with 3 M sodium thiocyanate. After exhaustive dialysis, the peak fractions of protein and VIIIC inhibitory activity (150-320 Bethesda units/ml) were radiolabeled with "2I by the chloramine T method (16) Crossed Immunoelectrophoresis. Crossed immunoelectrophoresis was done as previously described (5) with the following modifications: the agarose was 1%; the pH ofthe first dimension buffer was 8.6; the second dimension buffer contained 20% absorbed emu anti-VIIIC antiserum and 10 ,g ofaffinity-purified I25-radiolabeled anti-VIIIC antibody; and electrophoresis was at 5 mamp per slide in both dimensions. Crossed immunoelectrophoresis was also done after NaDodSOJpolyacrylamide gel electrophoresis (19) .
RESULTS
Purification of VIIIC from Commercial Factor VIII Concentrate. Table 1 presents data from a typical purification of VIIIC from commercial factor VIII concentrate. A 3,280-fold purification from commercial concentrate was achieved. This represents a 164,000-fold purification from plasma. Recoveries of VIIIC activity averaged 50% per step. The VIIIC preparations were contaminated with fibronectin and fibrinogen as determined by immunoassays and NaDodSO4polyacryla-mide gel analysis.
The purified VIIIC activity was increased up to 3-fold by catalytic amounts of thrombin over a 100-fold concentration range of purified VIIIC. A maximum 3-fold thrombin activation of VIIIC activity was also found for commercial factor VIII concentrate starting material and normal pooled plasma. However, maximum activation was reached in 10 min for the former two preparations and in 1 min for plasma. No VIIIRAg was detectable in these preparations in an assay that detects as little as 0.01 unit/ml. Thus, the VIIIC-VIIIRAg ratio was at least 105-fold greater than that in plasma.
Characterization of a Precipitating Heterologous Anti-VIIIC Antibody. The purified VIIIC was used as immunogen to produce an avian anti-VIIIC antiserum in an Australian emu. Anti-fibrinogen and anti-fibronectin antibodies were removed by absorption as described. The resultant antiserum produced only one immunoprecipitate arc when used in crossed immunoelectrophoresis ofpurified VIIIC (Fig. 1 ) and inhibited VIIIC procoagulant activity with a titer of 600-900 Bethesda units/ ml. After affinity purification and radiolabeling with 1251, it gave (Fig. 2) . The experiments in Figs. 1 and 2 provided direct evidence that the immunoprecipitate formed was specific for VIIIC protein. In Fig. 1 , VIIIC was subjected to crossed immunoelectrophoresis, and the lower half of the first-dimension agarose strip was sliced, extracted, and assayed for VIIIC activity. The resultant VIIIC activity peak showed an identical mobility to the immunoprecipitate arc. In Fig. 2, normal buffer. The first dimension was then divided in half horizontally, and the lower half was sliced vertically as illustrated. Each slice was extracted into 0.2 ml of assay buffer by shaking for 30 min at room temperature and then was assayed for VIIIC procoagulant activity. The remaining gel was run in the second dimension after replacing the missing portion of the first dimension with fresh agarose. The immunoprecipitate arc was identified with either Coomassie blue stain or autoradiography (the latter is shown). In the first dimension the anode is at the right, and in the second, at the top. (Lower) , and the 2.5-,&g sample was then used for crossed immunoelectrophoresis in the second dimension (Upper). The 20-pg. sample was stained with Coomassie blue and aligned with the second dimension. In order to allow proper alignment of the first and second dimensions, the position of the tracking dye was marked on the crossed immunoelectrophoresis slide, and the NaDodSO4 gel was photographically reduced to its original 9-cm height to compensate for gel swelling during Coomassie blue staining and destaining. The second dimension is an autoradiograph. In the first dimension, the anode is at the right; in the second dimension, it is at the top. staining doublet and multiple bands of higher Mr (Fig. 3 Lower), which were specifically identified as reacting with the antibody to VIIIC by crossed immunoelectrophoresis (Fig. 3 Upper). Without reduction, contaminating fibrinogen and fibronectin migrated only a short distance into the gel (Fig. 3 Lower Left) and did not react with the absorbed antiserum after crossed immunoelectrophoresis.
-To determine the Mrs ofthe multiple bands identified by the antibody as VIIIC, NaDodSOJpolyacrylamide gel electrophoresis was performed on reduced.samples of VIIIC. Fig. 4 shows the Mrs obtained for purified VIIIC (400 units/ml) (Fig. 4 Left) and for this purified VIIIC treated with thrombin (0.1 unit/ml) (Fig. 4 (12, (21) (22) (23) ) based on NaDodSO4 polyacrylamide gel electrophoretic data. Evidence -also has been presented' for a decrease in Mr of human VIIIC after thrombin treatment (10, 12, 21 (2) . However, high Mr forms of bovine VIIIC were not reported, and the bovine VIIIC bands consisted of a triplet (2) as compared with the strongly staining doublet described here. Another difference between purified human and bovine VIIIC is that the maximum level of thrombin activation of the human VIIIC isolated here was 3-fold, whereas purified bovine VIIIC was activated 30-fold by catalytic amounts of thrombin (2) . A recent report of thrombin activation of partially purified human VIIIC showed activation levels ranging from 2.5-to 13- fold (23) . Due to variations in experimental conditions, however, it is difficult to compare such data.
In conclusion, we have demonstrated that human VIIIC isolated from commercial factor VIII concentrate shows extensive size heterogeneity, ranging from Mr 79,000 to Mr 188,000. The identification of the multiple VIIIC bands was based on their reaction with a monospecific, precipitating, heterologous, anti-VIIIC antibody and on the decrease in molecular weight of all VIIIC bands after treatment ofVIIIC with catalytic amounts of thrombin. The VIIIC isolation method described here gave a high degree of purification of human VIIIC and can provide sufficient amounts of VIIIC for extensive analysis of its role in hemostasis.
